Investors

Corporate Profile

Raptor's mission is to research, produce and deliver medicines that improve life for patients with severe, rare diseases. Raptor is a NASDAQ-listed biopharmaceutical company with a product pipeline that may advance therapeutic options for 8 different indications and includes potential for both product launch and partnering revenue within the next 12 months.

Intellectual Property

Raptor owns or has exclusive licenses to protect its product candidates and drug-targeting platforms. To date, Raptor's patent portfolio includes patents relating to its delayed release cysteamine bitartrate and NeuroTrans™ technologies and patent applications covering cysteamine, Convivia™, NeuroTrans™ and HepTide™. Raptor also holds exclusive licenses covering WntTide, RP103 for cystinosis, cysteamine and related compounds for Huntingon's Disease, RP104 for NASH, tezampanel for pain, and tezampanel for thrombosis. Raptor periodically updates information on its Intellectual Property through Company press releases. Additional information can be obtained through the USPTO web site (www.uspto.gov).